Find therapies in clinical trials near you – page 2

Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma

Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Study on Bortezomib and Temozolomide for Patients with Recurrent Grade IV Glioma

Study on Bortezomib and Temozolomide for Patients with Recurrent Grade IV Glioma

Study of Selinexor, Bortezomib, and Lenalidomide with Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Study of Selinexor, Bortezomib, and Lenalidomide with Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Study on Bortezomib for Patients with Severe Autoimmune Encephalitis

Study on Bortezomib for Patients with Severe Autoimmune Encephalitis

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant